CTBC Brothers v Wei Chuan Dragons - CPBL

Jensen Huang throwing out the ceremonial first pitch to a CPBL game (Gene Wang/Getty Images)

Wall Street is gearing up for a monster earnings report from Nvidia

The average price target on Nvidia is up nearly 8% over the past month, its fastest growth this year.

8/26/25 6:18AM

Ever since Nvidia unofficially kicked off the AI boom in May 2023, we’ve tended to see a predictable routine among Wall Street analysts once every three months:

Get blown away by the chip designer’s quarterly results, and immediately ratchet up their price targets for how high the stock can climb thereafter.

However, ahead of Nvidia’s second-quarter report, due after the close on Wednesday, the sell side is trying something a little different. This time, analysts are scrambling to increase their price targets ahead of results, seemingly much more confident in the affirmation they’ll be getting on the longevity of the AI boom and Nvidia’s critical role in facilitating it.

Over the past month, the average price target for Nvidia among analysts polled by Bloomberg has increased by 7.7%, the fastest rate of growth this year. The second-biggest jump in price targets occurred in the wake of the chip designer’s first-quarter sales and earnings beat.

Those seeing more upside in the stock over the past month include:

Morgan Stanley, to $200 from $170
Piper Sandler, to $225 from $180
Susquehanna, to $210 from $180
KeyBanc Capital Markets, to $215 from $190
Wedbush Securities, to $210 from $175
UBS, to $205 from $175

“We believe Nvidia earnings on deck is another positive catalyst for tech stocks that will further remind investors this is still only the bottom of the 2nd inning in the 9 inning game around building out the AI Revolution over the coming years to enterprises/consumers globally,” Wedbush analyst Dan Ives wrote. “We continue to believe from our Asia field checks that demand to supply is 10:1 for Nvidia’s golden chips.”

Matt Phillips

SpaceX spectrum deal sends would-be rivals lower

Shares of struggling satellite services company EchoStar soared Monday, after the company — which had recently tottered close to bankruptcy — announced the sale of some of its wireless spectrum licenses to Tesla CEO Elon Musk’s SpaceX for $17 million.

The sale provides a competitive advantage to Musk’s growing Starlink satellite services business, as the licenses it is acquiring from Echostar allows Starlink to operate ground based broadband and cellphone services, the Wall Street Journal reported.

Entities that stood to be hurt by the emergence of a Musk-led SpaceX Starlink service got hit hard on the news. AST SpaceMobile, which has plans to offer a similar satellite-to-consumer cellular service, tumbled.

So did wireless tower providers like Crown Castle and American Tower. Low cost cellular service provider T-Mobile, which had a deal with SpaceX, also slumped, as Luke noted earlier, along with other large wireless telecommunication services providers.

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

SpaceX strikes $17B deal to buy EchoStar's spectrum for Starlink's direct-to-phone service | TechCrunch

The wireless telecommunications industry grouping within the S&P 500 was down more than 2.5% shortly after noon, making it the worst performing industry within the S&P 500 on Monday.

Robinhood, Amcor, Applovin surge on after being added to S&P 500

Robinhood, AppLovin vault higher as the "inclusion effect" is in full force

Membership has its privileges.

Matt Phillips3h

J. Edward Moreno

Hims rises, Novo dips after FDA releases “green list” of GLP-1 raw material suppliers

Hims & Hers rose and Novo Nordisk slipped in early trading after the US Food and Drug Administration released a "green list" of foreign GLP-1 ingredient suppliers that it considers in compliance with agency standards.

Some telehealth companies like Hims sell copycat versions of Novo's and Eli Lilly’s blockbuster weight-loss drugs through compounding pharmacies, which take the active ingredients from FDA-approved medications and make adjusted, or "personalized,” versions of the drug for patients.

Novo and Lilly have fought against this, arguing that it infringes on their intellectual property. They've sued smaller telehealth providers, pharmacies, and clinics in lieu of any action against them from the FDA. Instead, the FDA gave compounders a list of suppliers it deems safe.

Recent developments in the cases filed by the drugmakers so far as well as the FDA's recent actions suggest telehealth companies may be in a less risky position than investors previously thought. As of Monday morning, prediction markets pegged the likelihood of a suit from Novo against Hims at 34%, down from about 70% earlier this month.

Luke Kawa

Gold is outperforming the Nasdaq 100 since the launch of ChatGPT

There’s a bull market in anti-humanity.

J. Edward Moreno

UNH rises after saying it plans to reiterate outlook

UnitedHealth rose 2% in early trading after it disclosed that it plans to reiterate its full-year earnings outlook when it meets with investors this week.

The company said on July 29 that it was expects to report annual adjusted earnings per share of at least $16. The company had previously pulled full-year guidance and prior to that withdrawal, had told investors it expected to see earnings of $26 to $26.50 per share.

Currently, a analysts polled by FactSet are penciling in $16.23, compared to $17.21 before the guidance came down.

UnitedHealth has had a tumultuous year as he industry has been hit with rising costs of care, and UnitedHealth specifically has been hit with investigations into its Medicare Advantage practices. It recently got a boost after Warren Buffett's Berkshire Hathaway revealed that it's built a stake in the company